Judah Folkman dies

Judah Folkman, a proponent of the idea that halting angiogenesis could starve tumors, died yesterday at the age of 74. According to news reports, the cause of death was a heart attack. The promise of anti-angiogenesis therapies led to many high hopes for Folkman's work, particularly when the New York Times ran a linkurl:1998 story;http://www.amazon.com/Dr-Folkmans-War-Angiogenesis-Struggle/dp/0375502440 quoting James Watson's prediction that Folkman would cure cancer in two years. Folkman "wa

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Judah Folkman, a proponent of the idea that halting angiogenesis could starve tumors, died yesterday at the age of 74. According to news reports, the cause of death was a heart attack. The promise of anti-angiogenesis therapies led to many high hopes for Folkman's work, particularly when the New York Times ran a linkurl:1998 story;http://www.amazon.com/Dr-Folkmans-War-Angiogenesis-Struggle/dp/0375502440 quoting James Watson's prediction that Folkman would cure cancer in two years. Folkman "was upset about that," recalled Rakesh Jain, a colleague of Folkman's at Harvard. "He knew that it would take time. He was realistic about it. But he was also optimistic, " said Jain. That optimism inspired Folkman to continue pursuing anti-angiogenesis therapies after they failed to live up to their early hype, and in 2004, the FDA approved the linkurl:first biological therapy;http://www.cancer.gov/cancertopics/factsheet/AvastinFactSheet that blocked the formation of new blood vessels to tumors. "That optimism did translate into something," Jain told me by phone this afternoon. According to ISI, Folkman authored over 500 papers, which collectively accumulated nearly 75,000 citations. You can read here, in Folkman's own words, the linkurl:story of his discovery;http://www.the-scientist.com/article/display/13658/ of the first angiogenic protein. Jain met Folkman 25 years ago when Jain invited the researcher to give a talk on tumor pathophysiology to MIT students. When Jain moved to Harvard, Folkman continued to lecture for his students as recently as last September. Jain recalled Folkman as generous, creative, and with a vision that enabled him to connect different areas. "He inspired all of us to work in this area," Jain said. "I think he was a most incredible human being," Jain added. "This is so unexpected. We were going to celebrate his 75th birthday in a month." Have any stories about Folkman? Share them with us in a comment.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Alison McCook

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development